Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

• ClinicalTrials.gov Identifier: NCT02315768
• Recruitment Status: Active, not recruiting
• First Posted: December 12, 2014
• Last Update Posted: July 5, 2022
• Sponsor: University of California, San Diego
• Collaborator: Pharmacyclics LLC.
• Information provided by (Responsible Party): Thomas Kipps, University of California, San Diego

Study Description

Brief Summary:

The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL. This study will evaluate if ibrutinib in combination with GA101 - Obinutuzumab can reduce the amount of cancerous cells in body.

Condition or disease	Intervention/treatment	Phase
Chronic Lymphocytic Leukemia	Drug: GA101; Drug: ibrutinib	Phase 1; Phase 2

Detailed Description:

This is an open label phase IB/II clinical trial designed to determine the safety and clinical activity of Ibrutinib in combination with GA101 - Obinutuzumab. Safety, tolerability and dose-limiting toxicities (DLTs) will be evaluated during the initial cycle of treatment (Cycle 1; Day 1-28) as part of the phase Ib of this study (safety run-in).

In the phase II the response rate will be determined in all subjects that have received treatment. The study will enroll 32 subjects previously untreated who have active disease requiring treatment (as defined by IWCLL 2008 criteria for initiation of therapy). The study will include a Screening Phase, a Treatment Phase, and a Follow-up Phase. The Screening Phase assessments will be performed within 28 days prior to treatment. The Treatment Phase will extend from first dose until completion of all planned cycles of treatment (#6) or study drug discontinuation.

All subjects will receive Ibrutinib 420 mg (3 x 140-mg capsules) orally once daily for up to 6 cycles. The treatment with Ibrutinib will continue after cycle 6 for the following 3 years until disease progression, unacceptable toxicity or other reason for treatment discontinuation.

Subjects will undergo response assessment two months after completion of the study treatment. The initial follow-up evaluations will be made (after the response assessment) every 3 months during 9 months and later every 6 months until initiation of new treatment for CLL, consent withdrawal or death. During the long-term follow-up phase, subjects will be followed for survival (PFS, TFS and OS). The long-term follow-up phase will continue until disease progression, death, loss to follow up, consent withdrawal, or study end, whichever occurs first.

An evaluation of the End of Study will be performed due to initiation of new treatment for CLL or withdrawal of consent.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 32 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib
• Study Start Date: November 2015
• Estimated Primary Completion Date: November 2023
• Estimated Study Completion Date: November 2023

Arms and Interventions

Arm

Intervention/treatment

Experimental: GA101+ibrutinib; Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles. GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows: Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.; Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.; Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.; Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered.

Drug: GA101; Other Name: Obinutuzumab; Drug: ibrutinib

Outcome Measures

Primary Outcome Measures :

1. Phase IB Evaluate the safety, tolerability and dose limiting toxicity (DLT) of Ibrutinib in combination with Obinutuzumab in previously untreated CLL subjects. [ Time Frame: 4 weeks ]
2. Phase II Determine the overall response rate of Ibrutinib in combination with Obinutuzumab in previously untreated subjects with CLL. [ Time Frame: 2 years ]

Secondary Outcome Measures :

1. Determine progression-free survival (PFS), treatment-free survival (TFS) and overall survival (OS) in previously untreated CLL subjects that will receive treatment with Ibrutinib in combination with Obinutuzumab. [ Time Frame: 2 years ]
2. Negative minimal residual disease (MRDneg) [ Time Frame: 2 years ]

Eligibility Criteria

• Ages Eligible for Study: 65 Years and older (Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Diagnosis of CLL
2. Indication for treatment as defined by the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) Guidelines
3. No previous treatment for CLL

4. Males and females 65 years of age and older. Subjects under 65 years of age that meet any of the following criteria:

   A. Documented refusal to be treated with chemotherapy agents B. Subjects that are not candidates for treatment with chemotherapy based on poor performance status (ECOG g>= 2), Cumulative Illness Rating Scale (CIRS score) >= 6 or creatinine clearance less than 70 mL/min

5. Adequate hematologic, hepatic, and renal function
6. Anticipated survival of at least 6 months
7. Effective contraception is required while receiving Ibrutinib in combination with GA101-Obinutuzumab. For women of childbearing potential and men, effective contraception is required while receiving GA101-Obinutuzumab and for 365 days (12 months) after the last dose of the study drug

Exclusion Criteria:

1. Pregnant or nursing women
2. Treatment with chemotherapy, monoclonal antibodies, or biological agents (e.g. lenalidomide) other than the investigational agents during the time of participation in this trial
3. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
4. Severe or debilitating pulmonary disease
5. Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol.
6. History of second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or the breast, unless the tumor was successfully treated at least 2 years before trial entry and with no evidence of relapse or active cancer.
7. Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, human T-cell leukemia virus 1 (HTLV-1) seropositive status.
8. Evidence of active acute or chronic Hepatitis B (HBV)
9. Evidence of active Hepatitis C (HCV): subjects with positive hepatitis C serology and positive HCV RNA test
10. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
11. Known hypersensitivity to any of the study drugs
12. Major surgery (within 4 weeks prior to the start of Cycle 1), except for procedures that are performed for diagnostic purposes
13. Vaccination with a live vaccine within 28 days of the initiation of treatment.
14. Concomitant use of warfarin or other Vitamin K antagonists
15. Requirement to receive treatment with a strong cytochrome P450 (CYP) 3A inhibitor
16. Chronic liver disease with hepatic impairment (Child-Pugh class B or C)

Contacts and Locations

Locations

United States, California

UCSD Moores Cancer Center

La Jolla, California, United States, 92093

Sponsors and Collaborators

University of California, San Diego

Pharmacyclics LLC.

Investigators

• Principal Investigator: Thomas J. Kipps, MD, PhD; University of California, San Diego

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Castro JE, Lengerke-Diaz PA, Velez Lujan J, Choi MY, Moreno-Cortes EF, Forero JV, Garcia-Robledo JE, Jacobs C, McCarthy C, Heinen A, Amaya-Chanaga CI, Kipps TJ. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. Adv Hematol. 2022 Jan 22;2022:4450824. doi: 10.1155/2022/4450824. eCollection 2022.

• Responsible Party: Thomas Kipps, Deputy Director, University of California, San Diego
• ClinicalTrials.gov Identifier: NCT02315768
• Other Study ID Numbers: 141106
• First Posted: December 12, 2014
• Last Update Posted: July 5, 2022
• Last Verified: July 2022

Keywords provided by Thomas Kipps, University of California, San Diego:

CLL; Chronic Lymphocytic Leukemia; Ibrutinib; Obinutuzumab; Cancer

Additional relevant MeSH terms:

Leukemia; Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, B-Cell; Chronic Disease; Disease Attributes; Pathologic Processes; Obinutuzumab; Antineoplastic Agents, Immunological; Antineoplastic Agents